Stock Events

Stock Events

Monopar Therapeutics 

$62.62
36
-$0.5-0.79% Tuesday 20:00

Statistics

Day High
64.17
Day Low
60.68
52W High
102.05
52W Low
30.01
Volume
192,163
Avg. Volume
-
Mkt Cap
418.49M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

6AugExpected
Q2 2024
Q3 2024
Q1 2025
Q2 2025
Q3 2025
Q1 2026
Next
-1
-0.78
-0.57
-0.35
Expected EPS
-0.600615
Actual EPS
N/A

Financials

-Profit Margin
Unprofitable
2019
2020
2021
2022
2023
2024
0Revenue
-31.17MNet Income

Analyst Ratings

102Average Price Target
The highest estimate is 104.00.
From 2 ratings within the last 6 months. This is not an investment recommendation.
Buy
100%
Hold
0%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow MNPR. It's not an investment recommendation.
Alphabet
79493
GOOGL
Apple
69146
AAPL
Microsoft
64576
MSFT
Amazon
60260
AMZN

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Gilead Sciences
GILD
Mkt Cap166.82B
Gilead Sciences is a biopharmaceutical company that competes in developing treatments for life-threatening diseases, overlapping with Monopar's focus on severe and life-threatening diseases.
AMGEN
AMGN
Mkt Cap183.12B
Amgen is a biotech firm focusing on novel therapies, including for cancer and other serious illnesses, directly competing with Monopar's therapeutic development.
Bristol-Myers Squibb
BMY
Mkt Cap121.42B
Bristol Myers Squibb operates in the oncology space, developing cancer treatments that could compete with Monopar's cancer-focused pipeline.
Merck
MRK
Mkt Cap302.33B
Merck is known for its strong oncology portfolio, including therapies for various cancers, which competes with Monopar's cancer treatment developments.
Pfizer
PFE
Mkt Cap147.62B
Pfizer has a broad range of therapeutic products, including in oncology, which competes with Monopar's focus areas.
Abbvie
ABBV
Mkt Cap381.1B
AbbVie has a significant presence in oncology and other serious health conditions, competing with Monopar's therapeutic areas.
Regeneron Pharmaceuticals
REGN
Mkt Cap66.98B
Regeneron Pharmaceuticals focuses on developing drugs for serious diseases, including cancer, making it a competitor to Monopar.
Novartis
NVS
Mkt Cap290.05B
Novartis is a global healthcare company with a strong emphasis on research and development in oncology, competing with Monopar's focus.
Astrazeneca
AZN
Mkt Cap290.06B
AstraZeneca has a significant oncology portfolio, directly competing with Monopar's cancer therapy developments.
Johnson & Johnson
JNJ
Mkt Cap564.11B
Johnson & Johnson, through its pharmaceutical division Janssen, develops treatments for various diseases, including cancer, competing with Monopar's therapeutic focus.

About

Monopar Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. Its lead product candidate in development is Validive, a clonidine hydrochloride mucobuccal tablet that is in Phase 2b/3 clinical trial for the prevention of chemoradiotherapy induced severe oral mucositis in patients with oropharyngeal cancer. The company also engages in developing Camsirubicin, an analog of doxorubicin, which is in Phase 1b clinical trial for the treatment of advanced soft tissue sarcoma; MNPR-101, a urokinase plasminogen activator receptor targeted antibody for the treatment of various cancers; MNPR-101 RIT, a radioimmunotherapeutic based on MNPR-101 for the potential treatment of cancer and severe COVID-19; and MNPR-202, an analog of camsirubicin to potentially treat doxorubicin-and camsirubicin-resistant cancers. Monopar Therapeutics Inc. has collaborations with the Grupo Español de Investigación en Sarcomas for the development of camsirubicin in patients with advanced soft tissue sarcoma; NorthStar Medical Radioisotopes, LLC to develop radio-immuno-therapeutics targeting severe COVID-19; and the Cancer Science Institute of Singapore to evaluate the activity of MNPR-202 and related analogs in various types of cancer. The company was incorporated in 2014 and is headquartered in Wilmette, Illinois.
Show more...
CEO
Dr. Christopher M. Starr Ph.D.
Employees
14
Country
United States
ISIN
US61023L2079

Listings

STU
DE
1IY0.STU
MU
DE
1IY0.MU
F
DE
1IY0.F
XNAS
US
MNPR

0 Comments

Share your thoughts

FAQ

What is Monopar Therapeutics stock price today?▼
The current price of MNPR is $62.62 USD — it has decreased by -0.79% in the past 24 hours. Watch Monopar Therapeutics stock price performance more closely on the chart.
What is Monopar Therapeutics stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Monopar Therapeutics stocks are traded under the ticker MNPR.
Is Monopar Therapeutics stock price growing?▼
MNPR stock has fallen by -3.59% compared to the previous week, the month change is a +15.92% rise, over the last year Monopar Therapeutics has showed a +77.65% increase.
What is Monopar Therapeutics market cap?▼
Today Monopar Therapeutics has the market capitalization of 418.49M
When is the next Monopar Therapeutics earnings date?▼
Monopar Therapeutics is going to release the next earnings report on August 06, 2026.
What were Monopar Therapeutics earnings last quarter?▼
MNPR earnings for the last quarter are -0.46 USD per share, whereas the estimation was -0.67 USD resulting in a +31.7% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Monopar Therapeutics revenue for the last year?▼
Monopar Therapeutics revenue for the last year amounts to 0 USD.
What is Monopar Therapeutics net income for the last year?▼
MNPR net income for the last year is -31.17M USD.
How many employees does Monopar Therapeutics have?▼
As of May 27, 2026, the company has 14 employees.
In which sector is Monopar Therapeutics located?▼
Monopar Therapeutics operates in the Health & Wellness sector.
When did Monopar Therapeutics complete a stock split?▼
The last stock split for Monopar Therapeutics was on August 13, 2024 with a ratio of 1:5.
Where is Monopar Therapeutics headquartered?▼
Monopar Therapeutics is headquartered in Wilmette, United States.